Previous 10 | Next 10 |
2023-08-15 15:43:02 ET DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript August 15 2023, 08:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital ...
2023-08-14 16:23:20 ET DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q2 GAAP EPS of -$0.16 beats by $0.02 . DiaMedica reported total cash, cash equivalents and investments of $60.7 million, current liabilities of $1.9 million and working capital of $39.3 milli...
Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M “At-The-Market” Private Placement, Cash Runway Into 2026 Company Co...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Mo...
2023-08-06 04:08:12 ET Summary DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing recombinant proteins to treat life-threatening diseases. Its main clinical candidate, DM199, is undergoing evaluation in a Phase 2/3 study for the treatment of...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency. This year...
2023-06-27 02:52:23 ET Clinical stage biopharmaceutical company, DiaMedica Therapeutics ( NASDAQ: DMAC ) rose 4.5% to $4.40 on Monday late hours. The company filed Form 4 that shows executives and directors buying company stock. Director Randall Michael Giuf...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors. The Compan...
2023-06-21 11:50:49 ET DiaMedica Therapeutics ( NASDAQ: DMAC ) said the US Food and Drug Administration has lifted a hold on its Phase 2/3 clinical trial for its stroke drug candidate DM199 and that it has agreed to a $37.5M private placement of its stock to help fund the study. ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (“DiaMedica” or the “Company”), today announced it has entered into definitive agreements to sel...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
Conference Call and Webcast May 9 at 8:00 AM Eastern Time / 7:00 AM Central Time First Patient Dosed in Relaunch of ReMEDy2 Stroke Trial Clinical Operations Team Expanded to Support Global Expansion $46.5 Million Cash with Runway to 2026 DiaMedica Therapeut...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wed...